Cycloset bromocriptine mesylate regulatory update

Santarus Inc. (NASDAQ:SNTS, San Diego, Calif.) and VeroScience announced that Cycloset bromocriptine was included in the diabetes management algorithm published by the American Association of Clinical Endocrinologists (AACE). The algorithm recommended dual therapy to include Cycloset as an option in combination with metformin or another first-line therapy for patients with entry HbA1c >=7.5% and listed Cycloset as a treatment option for patients that need triple therapy and for those without symptoms with HbA1c >9%. The partners said the algorithm provides a neutral rating for Cycloset for hypoglycemia, weight gain, renal function, congestive heart failure and bone loss and a moderate rating for GI effects. The algorithm was created to guide primary care physicians, endocrinologists and other health care professionals to treat pre-diabetes and Type II diabetes, according to the partners. ...